Ventricular assist device (VAD) implantation has become an effective option for patients with severe heart failure. However, device-related infections remain a significant problem. The aim of this study was to describe the incidence and microbiological aetiology of bacteraemia in patients with VADs, and to assess the impact of bacteraemia on clinical outcomes.
A retrospective study was conducted of patients having VAD implantation at the Alfred Hospital (Melbourne, Australia) from October 1990 to July 2009. Medical records and microbiology databases were reviewed. Patients who were supported with a VAD for 72 h or more were evaluated for demographic data, VAD type, the occurrence of bacteraemia and clinical outcomes.
During the 19-year period, 135 VAD patients (89 Thoratec PVAD, 10 Novacor, and 36 Ventrassist) supported for a total duration of 17,304 (median 74) support days were included. Sixty-one patients (45%) developed VAD-associated bacteraemia, an incidence of 5.6 episodes per 1000 support days. The incidence of bacteraemia per 1000 days of support was similar for the three devices used: Thoratec PVAD, Novacor and Ventrassist VADs (7.8 ± 0.8, 5.2 ± 1.5 and 3.4 ± 0.5, respectively, p = 0.74). Staphylococcus aureus was the most common pathogen (25%). The rates of death on device, survival to transplant, recovery with explant and outcomes after transplantation, including 30-day mortality, median survival time and incidence of cerebrovascular accidents were not significantly impacted upon by bacteraemia.
Bacteraemia is common in VAD patients. However, the incidence of VAD-associated bacteraemia is independent of device type and with aggressive antimicrobial therapy; clinical outcomes need not be affected by the bacteraemia.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Heart, Lung and Circulation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Ventricular assist device-related infections.Lancet Infect Dis. 2006; 6: 426-437
- Mechanical circulatory support for the failing heart: past, present and future.Heart Lung Circ. 2005; 14: 163-166
- Bridging to transplant with the HeartMate left ventricular assist device: the Columbia Presbyterian 12-year experience.J Thorac Cardiovasc Surg. 2004; 127: 1309-1316
- LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection.J Heart Lung Transpl. 2003; 22: 914-921
- Infections during left ventricular assist device support do not affect posttransplant outcomes.Circulation. 2000; 102: III194-III199
- Nosocomial infections occurring during receipt of circulatory support with the paracorporeal ventricular assist system.Clin Infect Dis. 2002; 35: 1308-1315
- Multicentre clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation.J Thorac Cardiovasc Surg. 2001; 122: 1187
- Infection after implantation of pulsatile mechanical circulatory support devices.J Thorac Cardiovasc Surg. 2010; 139: 1632-1636
- Infectious complications in left ventricular assist device recipients.Clin Infect Dis. 1997; 24: 18-23
- Nosocomial bloodstream infections in patients with implantable left ventricular assist devices.Ann Thorac Surg. 2001; 72: 725-730
- Left ventricular assist device-related infection: treatment and outcome.Clin Infect Dis. 2005; 40: 1108-1115
- Effect of age on outcomes after left ventricular assist device placement.Transpl Proc. 2006; 38: 1496-1498
- Mechanical circulatory support for advanced heart failure: effect of patient selection on outcome.Circulation. 2001; 103: 231-237
- Do left ventricular assist device (LVAD) bridge to transplantation outcomes predict the results of permanent LVAD implantation?.Ann Thorac Surg. 2002; 74: 2051-2063
- VentrAssist left ventricular assist device: clinical trial results and Clinical Development Plan update.Eur J Cardiothorac Surg. 2007; 32: 735-744
- Infections complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era.Ann Thorac Surg. 2010; 90: 1270-1277
- Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart Experience in Europe.J Heart Lung Transpl. 2007; 26: 219-229
- Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation.Circulation. 1997; 95: 814-817
- Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators.Circulation. 2001; 104: 1029-1033
- Long-term use of a left ventricular assist device for end-stage heart failure.New Engl J Med. 2001; 345: 1435-1443
- Infection in permanent circulatory support: experience from the REMATCH trial.J Heart Lung Transpl. 2004; 23: 1359-1365
Published online: November 25, 2013
Accepted: September 16, 2013
Received in revised form: September 13, 2013
Received: January 29, 2013
© 2013 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier Inc. All rights reserved.